Cowen & Co.

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded Cepheid to a Neutral rating from Overweight, saying a manufacturing issue related to its Xpert cartridges could negatively impact fourth-quarter revenues.

Fluidigm first disclosed its renewed IPO effort in early December, reviving plans for a public offering that the company put on hiatus in September 2008 amid the economic downturn.

The vendors hope to help customers obtain funding from a new program called NIH Challenge Grants, which will set aside between $100 million and $200 million, and the National Centers for Research Resources, which will get an additional $300 million.

Nanogen's full-year revenues rose 23 percent, but the firm's cash holdings has fallen to nearly $3 million, which is not enough funding to support its plans for 2009.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.